Victor Moreno, Director of Clinical Research at START Madrid FJD, shared on LinkedIn:
“Today we woke up with the first positive Phase 3 study of an individualized neoantigen therapy and of an mRNA-based cancer therapy. Only a press release so, no real data mentioned, we will see at ESMO I hope.
Sadly, I have the impression that more people is talking today about Moderna stock price than about what this means for patients…”
Other articles about ESMO on OncoDaily.